Beyond the birth dose: China's strategic push to curb Hepatitis B
•On World Hepatitis Day 2026, China is expanding its viral hepatitis control strategy beyond high infant immunization rates to address adult screening gaps and life-cycle protection.
•Crucial to this progress is a rapid surge in domestic pharmaceutical innovation, highlighted by the approval of world-first therapies like an anti-hepatitis D antibody drug and a booming biotech expor...
•Together with community-level healthcare reforms, these breakthroughs support both national control efforts and global progress toward the WHO
هذا الخبر من CGTN EN. خبر يقدم أدوات ذكاء اصطناعي للتلخيص والترجمة والاستماع.
On World Hepatitis Day 2026, China is expanding its viral hepatitis control strategy beyond high infant immunization rates to address adult screening gaps and life-cycle protection. Crucial to this progress is a rapid surge in domestic pharmaceutical innovation, highlighted by the approval of world-first therapies like an anti-hepatitis D antibody drug and a booming biotech export sector. Together with community-level healthcare reforms, these breakthroughs support both national control efforts and global progress toward the WHOالمصدر: CGTN EN | Source: CGTN EN
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة CGTN EN. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by CGTN EN. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
